<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03163615</url>
  </required_header>
  <id_info>
    <org_study_id>2017002</org_study_id>
    <nct_id>NCT03163615</nct_id>
  </id_info>
  <brief_title>Effect of Tibet Rhodiola Capsule on Hypoxia and Cardiovascular Risk Factors in Patients With Obstructive Sleep Apnea</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Effect of Tibet Rhodiola Capsule on Hypoxia and Cardiovascular Risk Factors in Patients With Obstructive Sleep Apnea: A Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shao-Ping Nie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of Tibet Rhodiola Capsule on hypoxia and
      the cardiovascular risk factors in patients with mild to moderate OSA.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2017</start_date>
  <completion_date type="Anticipated">May 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average oxygen saturation</measure>
    <time_frame>Change from Baseline to 84±4days</time_frame>
    <description>Average oxygen saturation was assessed by home sleep apnea testing(HSAT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lowest saturation</measure>
    <time_frame>baseline and 84±4days</time_frame>
    <description>Lowest saturation in percentage(%) was assessed by home sleep apnea testing(HSAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of total sleep time associated with saturation lower than 90% (T90SaO2 )</measure>
    <time_frame>baseline and 84±4days</time_frame>
    <description>T90SaO2 in percentage(%) was assessed by home sleep apnea testing(HSAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AHI</measure>
    <time_frame>baseline and 84±4days</time_frame>
    <description>AHI was assessed by home sleep apnea testing(HSAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>baseline and 84±4days</time_frame>
    <description>Heart rate variability was assessed by Holter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary flow reserve</measure>
    <time_frame>baseline and 84±4days</time_frame>
    <description>Coronary flow reserve was assessed by Ultrasonic Cardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet(PLT) count</measure>
    <time_frame>baseline, 28±2days and 84±4days</time_frame>
    <description>PLT in 10^9/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low density lipoprotein-cholesterol(LDL-C)</measure>
    <time_frame>baseline, 28±2days and 84±4days</time_frame>
    <description>LDL-C in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycosylated hemoglobin (HbAlc)</measure>
    <time_frame>baseline and 84±4days</time_frame>
    <description>HbAlc in percentage(%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth sleepiness scale (ESS)</measure>
    <time_frame>baseline and 84±4days</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life scale (WHOQOL-BREF)</measure>
    <time_frame>baseline and 84±4days</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Tibet Rhodiola Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tibet Rhodiola Capsule</intervention_name>
    <description>4 capsules, po, from admission up to 84 days</description>
    <arm_group_label>Tibet Rhodiola Capsule</arm_group_label>
    <other_name>Xueyu Hongjingtian Huoli Jiaonang</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>4 capsules, po, from admission up to 84 days</description>
    <arm_group_label>Placebo oral capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;18 years, males or females;

          2. HSAT or PSG testing within recent 3 months;

          3. AHI 5-30 and lowest oxygen saturation&lt;85%;

          4. Refuse to accept CPAP, Mandibular orthosis device, surgery, or other medications to
             improve OSA;

          5. Written informed consent.

        Exclusion Criteria:

          1. History of CPAP, Mandibular orthosis device, surgery, or other medications to improve
             OSA;

          2. Significant central sleep apnea;

          3. Histories of other sleep disorders: insomnia, chronic sleep deprivation, long-term use
             of sleeping pills or sedatives, restless legs syndrome;

          4. Histories of underlying heart disease (cardiomyopathy, myocarditis, pericarditis or
             severe valvular disease), cardiogenic shock and heart failure (NYHA or Killip class
             3-4), persistent atrial or ventricular arrhythmias;

          5. History of myocardial infarction, coronary revascularization, and a known degree of
             stenosis &gt; 75% of the coronary lesions;

          6. Histories of known serious liver dysfunction (ALT or AST levels above 3 times the
             normal limit), renal insufficiency (GFR&lt;30ml/min), moderate and severe chronic
             obstructive pulmonary disease, and pulmonary arterial hypertension;

          7. Patients with malignant tumors, lymphoma and neuropsychiatric disorders;

          8. Patients with major surgery or trauma within 3 months, and active bleeding or
             cerebrovascular accident within 6 months;

          9. History of anemia (hemoglobin&lt;90g/L) or thrombocytopenia (thrombocyte &lt;90×10^9/L);

         10. Breastfeeding, pregnant, or potentially fertile women;

         11. Patients who have known to be allergic to Tibet Rhodiola Capsule or its components or
             patients with serious adverse effect;

         12. Participation in other clinical trials in recent 3 months;

         13. Patients who cannot complete this trial or comply with the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shao-Ping Nie, MD, PhD</last_name>
      <phone>86-10-84005256</phone>
      <email>spnie@126.com</email>
    </contact>
    <investigator>
      <last_name>Shao-Ping Nie, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2017</study_first_submitted>
  <study_first_submitted_qc>May 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2017</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Shao-Ping Nie</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

